Cargando…

Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy

The role of immune checkpoint inhibitors in metastatic lung cancer has been established in recent years and the pretherapeutic profiles of the tumor microenvironment in responders have been increasingly reported. The role of salvage surgery and the immune profiles of the posttherapeutic specimens in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Toshiko, Yoshida, Shigetoshi, Takami, Mariko, Ihara, Fumie, Yoshizawa, Hiroko, Toyoda, Takahide, Takeshita, Yuichiro, Nobuyama, Seiichi, Kanetsuna, Yukiko, Sato, Tetsuo, Yoshino, Ichiro, Motohashi, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942425/
https://www.ncbi.nlm.nih.gov/pubmed/31677359
http://dx.doi.org/10.1111/cas.14222
_version_ 1783484704418168832
author Kamata, Toshiko
Yoshida, Shigetoshi
Takami, Mariko
Ihara, Fumie
Yoshizawa, Hiroko
Toyoda, Takahide
Takeshita, Yuichiro
Nobuyama, Seiichi
Kanetsuna, Yukiko
Sato, Tetsuo
Yoshino, Ichiro
Motohashi, Shinichiro
author_facet Kamata, Toshiko
Yoshida, Shigetoshi
Takami, Mariko
Ihara, Fumie
Yoshizawa, Hiroko
Toyoda, Takahide
Takeshita, Yuichiro
Nobuyama, Seiichi
Kanetsuna, Yukiko
Sato, Tetsuo
Yoshino, Ichiro
Motohashi, Shinichiro
author_sort Kamata, Toshiko
collection PubMed
description The role of immune checkpoint inhibitors in metastatic lung cancer has been established in recent years and the pretherapeutic profiles of the tumor microenvironment in responders have been increasingly reported. The role of salvage surgery and the immune profiles of the posttherapeutic specimens in patients achieving an objective response have rarely been studied. We report a case of metastatic lung cancer treated by anti‐programmed death‐1 Ab followed by surgical resection. The immune status of the tumor was assessed, showing germinal center formation, memory B cell infiltration, and a high frequency of interferon gamma ‐secreting T cells.
format Online
Article
Text
id pubmed-6942425
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69424252020-01-07 Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy Kamata, Toshiko Yoshida, Shigetoshi Takami, Mariko Ihara, Fumie Yoshizawa, Hiroko Toyoda, Takahide Takeshita, Yuichiro Nobuyama, Seiichi Kanetsuna, Yukiko Sato, Tetsuo Yoshino, Ichiro Motohashi, Shinichiro Cancer Sci Case Report The role of immune checkpoint inhibitors in metastatic lung cancer has been established in recent years and the pretherapeutic profiles of the tumor microenvironment in responders have been increasingly reported. The role of salvage surgery and the immune profiles of the posttherapeutic specimens in patients achieving an objective response have rarely been studied. We report a case of metastatic lung cancer treated by anti‐programmed death‐1 Ab followed by surgical resection. The immune status of the tumor was assessed, showing germinal center formation, memory B cell infiltration, and a high frequency of interferon gamma ‐secreting T cells. John Wiley and Sons Inc. 2019-11-29 2020-01 /pmc/articles/PMC6942425/ /pubmed/31677359 http://dx.doi.org/10.1111/cas.14222 Text en © 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Kamata, Toshiko
Yoshida, Shigetoshi
Takami, Mariko
Ihara, Fumie
Yoshizawa, Hiroko
Toyoda, Takahide
Takeshita, Yuichiro
Nobuyama, Seiichi
Kanetsuna, Yukiko
Sato, Tetsuo
Yoshino, Ichiro
Motohashi, Shinichiro
Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
title Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
title_full Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
title_fullStr Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
title_full_unstemmed Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
title_short Immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
title_sort immunological features of a lung cancer patient achieving an objective response with anti‐programmed death‐1 blockade therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942425/
https://www.ncbi.nlm.nih.gov/pubmed/31677359
http://dx.doi.org/10.1111/cas.14222
work_keys_str_mv AT kamatatoshiko immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT yoshidashigetoshi immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT takamimariko immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT iharafumie immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT yoshizawahiroko immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT toyodatakahide immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT takeshitayuichiro immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT nobuyamaseiichi immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT kanetsunayukiko immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT satotetsuo immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT yoshinoichiro immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy
AT motohashishinichiro immunologicalfeaturesofalungcancerpatientachievinganobjectiveresponsewithantiprogrammeddeath1blockadetherapy